文献速递细菌感染、耐药与抗菌药物医院感染防控

实体器官移植受者多重耐药肠杆菌定植与感染的分子流行病学、自然史及长期结局

Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients.
PubMed 文献 · Clin Infect Dis · 2022-01-01

BACKGROUND: Multidrug-resistant Enterobacterales (MDR-E), including carbapenem-resistant and third-generation cephalosporin-resistant Enterobacterales (CRE, CefR-E), are major pathogens following solid organ transplantation (SOT).…

要点

  • 实体器官移植后多重耐药肠杆菌胃肠道定植常见,定植者感染风险显著增加。
  • 碳青霉烯类耐药肠杆菌定植者感染攻击率高于三代头孢耐药肠杆菌定植者。
  • 感染后短期死亡率低,但复发频繁且可发生于数年后。

核心结论

  • 实体器官移植后多重耐药肠杆菌胃肠道定植常见,并易导致定植菌株感染。
  • 多重耐药肠杆菌感染短期和长期死亡率低,但复发频繁且可晚至数年。
  • 全基因组测序提示存在未识别的克隆传播和耐药基因水平转移。

研究设计与样本

  • 前瞻性研究纳入2015年2月至2017年3月接受肺、肝、小肠移植的患者。
  • 移植后100天内每周采集直肠拭子培养多重耐药肠杆菌。
  • 对胃肠道定植和致病分离株进行全基因组测序。

主要发现

  • 25%(40/162)患者存在多重耐药肠杆菌胃肠道定植。
  • 碳青霉烯类耐药肠杆菌定植者攻击率53%,三代头孢耐药肠杆菌定植者21%(P = .049)。
  • 胃肠道定植和高体重指数是多重耐药肠杆菌感染的独立危险因素(P ≤ .004)。

关键数值与推荐

  • 多重耐药肠杆菌胃肠道定植率为25%(40/162)。
  • 碳青霉烯类耐药肠杆菌定植者攻击率53%,三代头孢耐药肠杆菌定植者21%(P = .049)。
  • 长期生存率(移植后中位4.3年)感染组71%,非感染组77%(P = .56)。

临床怎么用

  • 建议对实体器官移植受者进行多重耐药肠杆菌胃肠道定植监测。
  • 对定植患者应警惕后续感染风险,尤其是碳青霉烯类耐药肠杆菌定植者。
  • 感染幸存者需长期随访,关注晚期复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multidrug-resistant Enterobacterales (MDR-E), including carbapenem-resistant and third-generation cephalosporin-resistant Enterobacterales (CRE, CefR-E), are major pathogens following solid organ transplantation (SOT). METHODS: We prospectively studied patients who underwent lung, liver, and small bowel transplant from February 2015 through March 2017. Weekly perirectal swabs (up to 100 days post-transplant) were cultured for MDR-E. Whole-genome sequencing (WGS) was performed on gastrointestinal (GI) tract-colonizing and disease-causing isolates. RESULTS: Twenty-five percent (40 of 162) of patients were MDR-E GI-colonized. Klebsiella pneumoniae was the most common CRE and CefR-E. Klebsiella pneumoniae carbapenemases and CTX-M were leading causes of CR and CefR, respectively. Thirty-five percent of GI colonizers developed MDR-E infection vs 2% of noncolonizers (P < .0001). The attack rate was higher among CRE colonizers than CefR-E colonizers (53% vs 21%, P = .049). GI colonization and high body mass index were independent risk factors for MDR-E infection (P ≤ .004). Thirty-day mortality among infected patients was 6%. However, 44% of survivors developed recurrent infections; 43% of recurrences were late (285 days to 3.9 years after the initial infection). Long-term survival (median, 4.3 years post-transplant) did not differ significantly between MDR-E-infected and MDR-E-noninfected patients (71% vs 77%, P = .56). WGS phylogenetic analyses revealed that infections were caused by GI-colonizing strains and suggested unrecognized transmission of novel clonal group-258 sublineage CR-K. pneumoniae and horizontal transfer of resistance genes. CONCLUSIONS: MDR-E GI colonization was common following SOT and predisposed patients to infections by colonizing strains. MDR-E infections were associated with low short- and long-term mortality, but recurrences were frequent and often occurred years after initial infections. Findings provide support for MDR-E surveillance in our SOT program.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hong Nguyen M, Shields RK, Chen L, et al. Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients. Clin Infect Dis. 2022. PMID: 33970222. doi:10.1093/cid/ciab427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。